NCT04656028Active, not recruiting
Genetic Testing and Motivational Counseling for FH
Impact of Genetic Testing and Motivational Counseling on the Adherence to Healthy Lifestyle and Hypolipidemic Therapy and Efficiency of Cascade Screening in Patients With Familial Hypercholesterolemia (GENMOTIV-FH)
Source: ClinicalTrials.gov · Last updated 17 Dec 2024
Brief summary (registry, in English)
To date, there are highly effective lipid-lowering drugs, the combination of which makes it possible to achieve the target level of LDL-C in most patients with familial hypercholesterolemia (FH). However, the effectiveness of treatment of FH patients strongly depends on adherence to lipid-lowering therapy and to the healthy lifestyle, as well as the detection of the disease and the therapy prescription as early as possible, better in childhood. The aim of the study is to assess the impact of genetic testing and motivational counseling on the effectiveness of treatment and cascade screening in patients with FH.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- First submitted
- 30 Nov 2020
- Start date
- 15 Jun 2020
- Primary completion date
- 30 Jan 2025
- Lead sponsor
- National Medical Research Center for Therapy and Preventive Medicine
- Diseases
- Familial hypercholesterolaemia
- NCT number
- NCT04656028
What you commit to
- Study type: Interventional
- Planned participants: 180
- From 15 Jun 2020 to the primary completion date, 30 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Established active severe infectious disease or severe hematologic, metabolic, gastrointestinal or endocrine dysfunctions (for example, uncontrolled thyroid dysfunction or uncontrolled diabetes mellitus) in the opinion of the investigator
- Active liver disease
- Any other conditions at Visit 1 that, according to the investigator's opinion, render the patient ineligible for inclusion in the study, may interfere with the patient's participation in the study or patient's completion of the study.
Lab values
- Estimated GFR≤ 30 ml / min / 1.73m2
Other
- Pregnancy or lactation at the time of enrollment
Who the study is looking for
- Probable or definite diagnosis of FH according to the Dutch criteria (6 points or more);
- Signed informed consent;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Medical Research Centre for Therapy and Preventive Medicine of the Ministry of Health of Russia Coordinator of this site? Confirm its status | Moscow | Russia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.